A team of U.S. and South African researchers has identified and cloned an antibody that targets one of the few unchanging regions of HIV.
For several years now, scientists working on an HIV vaccine have been focused on a small set of patients whose immune systems were able to generate rare antibodies able to vanquish most strains of the lethal virus. And over the weekend a team of scientists from South Africa and the U.S. say that one woman--dubbed CAP256-VRC26--may have offered a key to do just that.
The antibody upstart Igenica has rounded up $14 million in venture cash to move its lead drug into the clinic. The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures all participated in the round.
The British biotech has rounded up $28 million (£17.5 million) in first-round venture cash from a group of marquee investors willing to bet big that Crescendo's mouse platform can deliver the best in cutting-edge antibody fragment therapeutics.
Amgen, Celgene and Eli Lilly joined forces with some prominent venture players to back a $26 million round for Sutro Biopharma, a San Francisco-based biotech which has been garnering some careful scrutiny for its work on antibodies.
As Visterra readies an influenza antibody for Phase I trials, the Gates-foundation-backed biotech announced today it's hired veterans of Mascoma and Concert Pharmaceuticals and licensed an antibody to treat the dengue virus out of the MIT lab of its co-founder, Dr. Ram Sasisekharan.
The Strüngmann brothers' expensive taste for biotech companies has helped generate another big venture round for Ganymed Pharmaceuticals, a German biotech with claims to some cutting-edge cancer drug technology.
The intense R&D focus in biopharma R&D circles on the therapeutic punch of cancer immunotherapies hasn't escaped the notice of top analysts, who are making some megablockbuster projections on the commercial impact these new drugs are likely to have.
Two years after Takeda acquired Nycomed, it's opted to punt a troubled partnership it inherited with Immunomedics on an anti-CD20 antibody pact struck 5 years ago for up to $620 million.
When Johnson & Johnson does an R&D event, they often like to make a flourish--walking the walk as they talk the talk. That high-impact style was on full display in London today as the pharma giant spearheaded a $42 million venture investment in an up-and-coming antibody developer, inked one collaboration pact on immune-mediated diseases and a second vaccine research partnership that will connect with a pair of biotechs and a research institute.